Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05450861
Other study ID # KMUHIRB-F(I)-20190142
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 3, 2020
Est. completion date February 4, 2021

Study information

Verified date July 2022
Source Kaohsiung Medical University Chung-Ho Memorial Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

According to the World Health Organization data, one out of every five Chinese men has a hair loss symptom, and the hair loss is as high as 84% before the age of 30. Based on the experience of clinicians, there seems to be an increasing trend of alopecia patients who seek the treatment in Taiwan. Treating pathological hair loss requires prompt diagnosis and management to prevent conditions that could lead to permanent hair loss. The current methods of treating hair loss include oral drugs, topical medication, laser illuminating treatment, platelet-rich plasma and hair transplant surgery. However, these treatments also have different disadvantages. Prolonged continuous use of oral and topical medications may be accompanied by side effects. Other treatment modalities may require higher costs, require return visits, or be more invasive. Previous study found that the composition of small DNA fragments (SF DNA) possesses not only toxin-free in primary human skin cells and nude mice, but also inhibits inflammation and ROS generation in the process of skin aging. SF DNA also contributes to promote the proliferation and differentiation of hair follicles, and stimulates the hair growth in nude mice through affecting JAK-STAT pathway. The investigators hypothesize that the clinical application of SF DNA scalp conditioning solution attenuates inflammatory responses, promotes the proliferation and differentiation of hair follicles, and increases the hair of hair loss patients and inspires the quality of life.


Description:

Thick and healthy hair is a symbol, representing the attractiveness, youth, health and fertility of adults. However, according to the World Health Organization data, one out of every five Chinese men has a hair loss symptom, and the hair loss is as high as 84% before the age of 30. Based on the experience of clinicians, there seems to be an increasing trend of alopecia patients who seek the treatment in Taiwan. Excessive hair shedding potentially distributes to physiological effect which is in the senile hair-loss/postpartum state, or pathological effect which is due to thyroid disturbances, trauma, lupus erythematosus, scleroderma, drug effects, iron deficiency, or fungal infection. There are also two kinds of pathological hair loss, alopecia areata and androgen-derived hair loss, both of them are difficult to treatment in clinical so far. First-line interventions for treating excessive hair shedding include lifestyle modification and behavior therapy, such as clean scalp, adjusted daily routine, and alleviated psychological stress. The second-line interventions is drug therapy which is helpful in the treatment of excessive hair shedding, but respond to conservative measures. The minoxidil application is an effective treatment for androgenetic alopecia in both men and women. Its side effects include redness and scaling of the scalp. The finasteride reduces the dihydrotestosterone (DHT) in the serum and scalp, but it may cause sexual dysfunction. However, laser illuminating treatment, platelet-rich plasma (PRP) treatment, and surgical (hair transplant surgery) are cataloged to third-line interventions. The PRP treatment is safe, rapid, and process tolerable, and has the advantage of being finer and relatively low-cost compared to hair transplantation. Follicular units pre-treatment by PRP also facilitate increase of the survival rate of transplanted hair. Although light therapy does not have the side effects of percutaneous or oral administration, treatment with two to three times a week can also cause problems for patients. Autologous hair transplantation is a supplementary treatment for advanced androgenetic alopecia. However, the cost of hair transplantation is high, and the survival rate of hair after transplantation is also worrying. In addition, surgery during convalescence also produces the costs of hospitalization and the loss of productivity. These problems are worthwhile for most patients with excessive hair shedding. To minimize invasiveness treatment, the efficacy, safety, and cost-effectiveness should be considered. Our previous study found that the composition of small DNA fragments (SF DNA) possesses not only toxin-free in primary human skin cells and nude mice, but also inhibits inflammation and ROS generation in the process of skin aging. SF DNA also contributes to promote the proliferation and differentiation of hair follicles, and stimulates the hair growth in nude mice through affecting JAK-STAT pathway. The investigators hypothesize that the clinical application of SF DNA scalp conditioning solution attenuates inflammatory responses, promotes the proliferation and differentiation of hair follicles, and increases the hair of hair loss patients and inspires the quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date February 4, 2021
Est. primary completion date February 4, 2021
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria: - Patients within 20~75 years old. - Diagnosed with alopecia by dermatologists. - Willing to maintain the same hair style, color, shampoo and hair products used, and approximate hair length starting from signing ICF and throughout the study. - The subject can understand and obey order. Exclusion Criteria: - Pregnant, nursing, or planning a pregnancy during the study. - Use of any topical medication (such as minoxidil or any other solution for hair growth), laser therapy, or chemotherapy, within the preceding 4 weeks. - Personal medical history of abnormal blood clotting such as bleeding disorders or platelet dysfunction syndrome. - Personal medical history of unstable vital signs such as hypotension or uncontrolled hypertension syndrome. - Prior hair transplant. - Chronic scalp disorders that require medications. - Uses medication known to cause hair thinning such as Coumadin and anti- depressants/anti-psychotics. - Existing scalp diseases such as folliculitis, scalp psoriasis, seborrheic dermatitis, or inflammatory scalp conditions. - Enrolled in any other medical study or has been enrolled in any medical study in the past 6 months. - Any hematologic abnormalities. - Severe allergies manifested by a history of anaphylaxis, or history or presence of multiple severe allergies. - Planned upcoming surgeries. - Tattoo on scalp.

Study Design


Intervention

Other:
SF DNA extraction composition
the composition of small fragments of DNA from fish
Placebo
the scalp conditioning solution without SF DNA extraction composition

Locations

Country Name City State
Taiwan Kaohsiung Municipal Ta-Tung Hospital Kaohsiung

Sponsors (1)

Lead Sponsor Collaborator
Kaohsiung Medical University Chung-Ho Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

References & Publications (1)

Hsu WL, Lu JH, Noda M, Wu CY, Liu JD, Sakakibara M, Tsai MH, Yu HS, Lin MW, Huang YB, Yan SJ, Yoshioka T. Derinat Protects Skin against Ultraviolet-B (UVB)-Induced Cellular Damage. Molecules. 2015 Nov 12;20(11):20297-311. doi: 10.3390/molecules201119693. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other hair density using the hair scalp analysis device to measure hair density at the vertex baldness site. 4 weeks
Other hair diameter using the hair scalp analysis device to measure hair diameter at the vertex baldness site. 4 weeks
Other DLQI questionnaire Participants answered the DLQI questionnaire by self. Higher scores mean a worse outcome (poor quality of life). 4 weeks
Primary hair density using the hair scalp analysis device to measure hair density at the vertex baldness site. 8 weeks
Primary hair diameter using the hair scalp analysis device to measure hair diameter at the vertex baldness site. 8 weeks
Secondary Dermatology Life Quality Index (DLQI) questionnaire Participants answered the DLQI questionnaire by self. Higher scores mean a worse outcome (poor quality of life). 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06110377 - MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine) Phase 4
Recruiting NCT05611593 - Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia Phase 1
Completed NCT03676400 - Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia N/A
Recruiting NCT05938569 - Computer-Assisted Hair Restoration Study Using ARTAS System N/A
Not yet recruiting NCT06326359 - Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia N/A
Recruiting NCT05426629 - Hydraderm for Androgenic Alopecia Phase 4
Recruiting NCT05369481 - Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia N/A
Recruiting NCT05827991 - A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia N/A
Not yet recruiting NCT06292533 - Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study N/A
Completed NCT02824380 - Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Phase 1
Completed NCT06112782 - Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality N/A
Completed NCT02594046 - The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia N/A
Recruiting NCT05435625 - Fractional Laser Versus Radiofrequency in Androgenetic Alopecia N/A
Completed NCT03506503 - Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia N/A
Completed NCT03467412 - To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Phase 2
Completed NCT01852487 - Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia N/A
Not yet recruiting NCT03474718 - Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Early Phase 1
Active, not recruiting NCT02914587 - Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study N/A
Completed NCT04341363 - Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling N/A
Completed NCT04450602 - A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss N/A